Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose‐finding study
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Aims: Ipragliflozin is a novel, selective inhibitor of sodium glucose co‐transporter 2 ( SGLT2 inhibitor) in clinical development for type 2 diabetes mellitus ( T2DM ) treatment. This study assessed the efficacy and safety of different doses of ipragliflozin. Methods: In a 12‐week, multicentre, double‐blind, randomized, placebo‐controlled, dose‐finding study patients with inadequate glycaemic control on metformin monotherapy (≥1500 mg/day) were randomized to one of four ipragliflozin treatment groups (12.5, 50, 150 or 300 mg once daily) or placebo. Primary efficacy outcome was mean change from baseline in haemoglobin A1c ( HbA1c ) compared to placebo at week 12. Adverse events ( AEs ), vital signs and laboratory safety measurements were assessed. Results: Ipragliflozin dose dependently decreased HbA1c from baseline to week 12 compared to placebo (−0.22, −0.34, −0.40 and −0.48% for ipragliflozin 12.5, 50, 150 and 300 mg, respectively). Decreases in body weight and blood pressure were observed for all ipragliflozin groups. AEs occurred in 39.7–51.4% of the ipragliflozin groups and 39.4% of placebo patients. Urinary tract infections (1.4–6.9 vs. 6.1%), genital infections (0–4.3 vs. 1.5%) and hypoglycaemia (0–5.9 vs. 3.0%) were similar in the ipragliflozin and placebo groups, respectively, without dose dependency. There were no clinically relevant effects on other safety measurements. Conclusions: Ipragliflozin treatment improved glycaemic control when added to metformin therapy and may be associated with weight loss and reductions in blood pressure compared to placebo. No safety or tolerability concerns were identified at any of the tested doses supporting the further development of ipragliflozin at ≥50 mg doses in T2DM patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EuroQol: the current state of play
Brooks, R. (1996) · Health Policy · doi:10.1016/0168-8510(96)00822-6 · Cited by 5,815 · cited 2×
“For PROs, changes from baseline to week 12 in EQ-5D domains and ADDQoL scores were small across all treatment groups but with a non-statistically significant trend for improvement in the ipragliflozin treatment groups (Table S1, Supporting Information).”
MethodStandards of medical care in diabetes—2013
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc13-s011 · Cited by 4,369
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Self-citationInfluence of Weight Reduction on Blood Pressure: A Meta-Analysis of Randomized Controlled Trials
Neter, J. E., Stam, B. E., Kok, F. J., Grobbee, D. E., & Geleijnse, J. M. (2003) · Hypertension · doi:10.1161/01.hyp.0000094221.86888.ae · Cited by 1,391
Defining and Reporting Hypoglycemia in Diabetes
American Diabetes Association Workgroup on Hypoglycemia (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1245 · Cited by 1,146
Bolinder, J., Ljunggren, Ö., Kullberg, J., Johansson, L., Wilding, J., Langkilde, A. M., Sugg, J., & Parikh, S. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2260 · Cited by 867 · cited 12×
“In another 24-week dapagliflozin metformin add-on study in patients with T2DM [21], weight loss was predominantly explained by reduced total body fat mass, with reductions in both visceral adipose tissue and subcutaneous adipose tissue volume.”
BackgroundInfluentialSelf-citationSodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
List, J. F., Woo, V., Morales, E., Tang, W., & Fiedorek, F. T. (2009) · Diabetes Care · doi:10.2337/dc08-1863 · Cited by 698
Cited by
Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes: A Systematic Review and Meta-analysis
Vasilakou, D., Karagiannis, T., Athanasiadou, E., Mainou, M., Liakos, A., Bekiari, E., Sarigianni, M., Matthews, D. R., & Tsapas, A. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-4-201308200-00007 · Cited by 911
Scheen, A. J. (2015) · Drugs · doi:10.1007/s40265-014-0337-y · Cited by 554
Wu, J. H. Y., Foote, C., Blomster, J., Toyama, T., Perkovic, V., Sundström, J., & Neal, B. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)00052-8 · Cited by 474
Baker, W. L., Smyth, L. R., Riche, D. M., Bourret, E. M., Chamberlin, K. W., & White, W. B. (2014) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2014.01.007 · Cited by 452
Chino, Y., Samukawa, Y., Sakai, S., Nakai, Y., Yamaguchi, J., Nakanishi, T., & Tamai, I. (2014) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.1909 · Cited by 389
Metadata
- Authors
- Wilding, J. P. H., Ferrannini, E., Fonseca, V. A., Wilpshaar, W., Dhanjal, P., & Houzer, A.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2012-12-07
- Volume
- 15
- Issue
- 5
- Pages
- 403-409
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2137467405
- Cited by
- 116
- References
- 7
- FWCI
- 10.58
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose‐finding study. https://app.cochat.ai/papers/10.1111/dom.12038
- The paper
- Wilding, J. P. H., Ferrannini, E., Fonseca, V. A., Wilpshaar, W., Dhanjal, P., & Houzer, A. (2013). Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose‐finding study. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.12038
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.